Glimepiride – 500 mg

Brand:
Cayman
CAS:
93479-97-1
Storage:
-20
UN-No:
De Minimis - 2811 / 6.1

Glimepiride is a long-acting sulfonylurea that inhibits ATP-sensitive potassium (KATP) channels in pancreatic β-cells (IC50 = 3 nM), which leads to the release of insulin.{25521} At 20 μM, glimepiride has been shown to increase the activity of intracellular insulin receptors and to prevent insulin receptor downregulation during chronic insulin stimulation through a mechanism involving protein kinase C activation.{25523} It has been reported to be less effective at inhibiting nonpancreatic KATP channels, and therefore contributes fewer cardiac actions, compared to earlier generations of sulfonylurea anti-type 2 diabetes treatments.{25522}  

 

Available on backorder

SKU: 12090 - 500 mg Category:

Description

A long-acting sulfonylurea that inhibits KATP channels in pancreatic β-cells (IC50 = 3 nM), which leads to the release of insulin; increases the activity of intracellular insulin receptors and prevents insulin receptor downregulation during chronic insulin stimulation through a mechanism involving PKC activation


Formal name: 3-ethyl-2,5-dihydro-4-methyl-N-[2-[4-[[[[(trans-4-methylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]-2-oxo-1H-pyrrole-1-carboxamide

Synonyms:  HOE 490

Molecular weight: 490.6

CAS: 93479-97-1

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Ion Channel Modulation|Blockers||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Diabetes